Adaptive Pathways: Earlier Access, But What About Data Exclusivity And SPCs?
This article was originally published in SRA
Executive Summary
The European Medicines Agency said recently that its adaptive pathways project had been successful in helping to facilitate the development and approval of new drugs via iterative evidence gathering, and that it was planning to incorporate the lessons learned from the pilot into the mainstream drug development process1.